| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sleep Apnea, Obstructive | 146 | 2024 | 1875 | 11.330 |
Why?
|
| Pharynx | 53 | 2022 | 432 | 4.540 |
Why?
|
| Pharyngeal Muscles | 29 | 2023 | 81 | 4.530 |
Why?
|
| Continuous Positive Airway Pressure | 54 | 2022 | 575 | 4.420 |
Why?
|
| Polysomnography | 86 | 2024 | 1848 | 3.610 |
Why?
|
| Sleep Apnea Syndromes | 44 | 2024 | 975 | 3.250 |
Why?
|
| Respiration | 51 | 2022 | 1656 | 3.090 |
Why?
|
| Respiratory Muscles | 27 | 2013 | 142 | 3.070 |
Why?
|
| Respiratory Mechanics | 31 | 2014 | 699 | 2.890 |
Why?
|
| Airway Resistance | 42 | 2024 | 406 | 2.760 |
Why?
|
| Sleep | 78 | 2023 | 4768 | 2.650 |
Why?
|
| Sleep Stages | 40 | 2021 | 694 | 2.430 |
Why?
|
| Arousal | 29 | 2023 | 1166 | 2.260 |
Why?
|
| Tongue | 31 | 2023 | 403 | 2.180 |
Why?
|
| Wakefulness | 40 | 2023 | 1265 | 2.000 |
Why?
|
| Sleep, REM | 24 | 2022 | 595 | 1.800 |
Why?
|
| Electromyography | 68 | 2023 | 1394 | 1.740 |
Why?
|
| Mandibular Advancement | 6 | 2022 | 64 | 1.660 |
Why?
|
| Pulmonary Ventilation | 20 | 2014 | 372 | 1.480 |
Why?
|
| Positive-Pressure Respiration | 11 | 2009 | 639 | 1.450 |
Why?
|
| Facial Muscles | 6 | 2022 | 159 | 1.070 |
Why?
|
| Hypercapnia | 15 | 2016 | 261 | 1.000 |
Why?
|
| Respiratory Physiological Phenomena | 12 | 2013 | 189 | 0.990 |
Why?
|
| Carbon Dioxide | 15 | 2010 | 1147 | 0.960 |
Why?
|
| Automobile Driving | 3 | 2013 | 441 | 0.900 |
Why?
|
| Pressure | 28 | 2019 | 1154 | 0.900 |
Why?
|
| Epiglottis | 11 | 2022 | 81 | 0.830 |
Why?
|
| Reflex | 13 | 2011 | 376 | 0.800 |
Why?
|
| Hypoglossal Nerve | 8 | 2014 | 108 | 0.790 |
Why?
|
| Airway Obstruction | 11 | 2022 | 661 | 0.770 |
Why?
|
| Signal Processing, Computer-Assisted | 6 | 2010 | 1496 | 0.760 |
Why?
|
| Motor Neurons | 13 | 2012 | 870 | 0.740 |
Why?
|
| Diagnosis, Computer-Assisted | 4 | 2013 | 710 | 0.730 |
Why?
|
| Lung Volume Measurements | 12 | 2012 | 375 | 0.710 |
Why?
|
| Muscle Contraction | 8 | 2018 | 1201 | 0.670 |
Why?
|
| Hypnotics and Sedatives | 8 | 2021 | 1179 | 0.650 |
Why?
|
| Ventilators, Negative-Pressure | 8 | 2011 | 13 | 0.650 |
Why?
|
| Sleep Apnea, Central | 6 | 2014 | 88 | 0.610 |
Why?
|
| Home Care Services | 3 | 2013 | 648 | 0.550 |
Why?
|
| Oxygen Inhalation Therapy | 5 | 2018 | 411 | 0.540 |
Why?
|
| Male | 201 | 2024 | 360846 | 0.530 |
Why?
|
| Trazodone | 2 | 2014 | 68 | 0.530 |
Why?
|
| Bariatric Surgery | 2 | 2024 | 992 | 0.530 |
Why?
|
| Adult | 160 | 2024 | 221210 | 0.520 |
Why?
|
| Palatal Muscles | 5 | 2003 | 15 | 0.500 |
Why?
|
| Humans | 257 | 2024 | 761596 | 0.490 |
Why?
|
| Monitoring, Ambulatory | 3 | 2011 | 354 | 0.470 |
Why?
|
| Middle Aged | 136 | 2024 | 220921 | 0.470 |
Why?
|
| Respiratory Function Tests | 8 | 2014 | 1682 | 0.460 |
Why?
|
| Losartan | 1 | 2016 | 265 | 0.460 |
Why?
|
| Acoustic Stimulation | 1 | 2018 | 1235 | 0.450 |
Why?
|
| Models, Biological | 10 | 2015 | 9469 | 0.430 |
Why?
|
| Obesity | 15 | 2024 | 12947 | 0.430 |
Why?
|
| G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2013 | 61 | 0.430 |
Why?
|
| Manometry | 2 | 2006 | 454 | 0.420 |
Why?
|
| Muscles | 6 | 2016 | 1576 | 0.420 |
Why?
|
| Inhalation | 7 | 2017 | 143 | 0.420 |
Why?
|
| Weight Loss | 1 | 2024 | 2684 | 0.420 |
Why?
|
| Osteoporotic Fractures | 3 | 2023 | 411 | 0.420 |
Why?
|
| Quality of Life | 7 | 2017 | 13367 | 0.420 |
Why?
|
| Muscle, Skeletal | 10 | 2017 | 4948 | 0.410 |
Why?
|
| Sex Characteristics | 6 | 2005 | 2639 | 0.410 |
Why?
|
| Female | 155 | 2024 | 392705 | 0.410 |
Why?
|
| Desipramine | 3 | 2017 | 182 | 0.410 |
Why?
|
| Hot Flashes | 5 | 2016 | 330 | 0.400 |
Why?
|
| Heart Rate | 11 | 2021 | 4195 | 0.390 |
Why?
|
| Mouth Breathing | 6 | 2024 | 25 | 0.390 |
Why?
|
| Pharyngeal Diseases | 3 | 2018 | 134 | 0.380 |
Why?
|
| Palate, Soft | 5 | 2018 | 100 | 0.380 |
Why?
|
| Posture | 4 | 2020 | 957 | 0.380 |
Why?
|
| Electroencephalography | 16 | 2018 | 6237 | 0.370 |
Why?
|
| Palate | 5 | 2022 | 124 | 0.370 |
Why?
|
| Oxygen | 15 | 2022 | 4227 | 0.370 |
Why?
|
| Respiratory System | 9 | 2018 | 563 | 0.370 |
Why?
|
| Muscle Hypotonia | 2 | 2022 | 161 | 0.360 |
Why?
|
| Oropharynx | 3 | 2022 | 138 | 0.340 |
Why?
|
| Altitude | 2 | 2010 | 163 | 0.340 |
Why?
|
| Mandelic Acids | 2 | 2020 | 46 | 0.340 |
Why?
|
| Patient Compliance | 5 | 2016 | 2690 | 0.330 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2015 | 3204 | 0.330 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 1039 | 0.320 |
Why?
|
| Mechanoreceptors | 5 | 2010 | 188 | 0.320 |
Why?
|
| Vital Signs | 1 | 2010 | 144 | 0.310 |
Why?
|
| Electric Stimulation Therapy | 1 | 2014 | 628 | 0.310 |
Why?
|
| Nasal Cavity | 6 | 2009 | 304 | 0.310 |
Why?
|
| Wrist | 3 | 2004 | 227 | 0.300 |
Why?
|
| Patient Admission | 1 | 2015 | 1367 | 0.290 |
Why?
|
| Electrocardiography | 6 | 2018 | 6377 | 0.290 |
Why?
|
| Automation | 1 | 2010 | 586 | 0.290 |
Why?
|
| Diaphragm | 6 | 2022 | 351 | 0.280 |
Why?
|
| Cross-Over Studies | 10 | 2020 | 2079 | 0.280 |
Why?
|
| Specialization | 2 | 2005 | 778 | 0.280 |
Why?
|
| Blood Pressure | 4 | 2016 | 8481 | 0.270 |
Why?
|
| Severity of Illness Index | 16 | 2019 | 15843 | 0.270 |
Why?
|
| Equipment Design | 7 | 2014 | 3511 | 0.260 |
Why?
|
| Lung | 6 | 2018 | 10002 | 0.260 |
Why?
|
| Air Pressure | 6 | 2012 | 74 | 0.260 |
Why?
|
| Oximetry | 8 | 2020 | 459 | 0.250 |
Why?
|
| Adrenergic Uptake Inhibitors | 4 | 2020 | 186 | 0.250 |
Why?
|
| Chemoreceptor Cells | 3 | 2010 | 89 | 0.250 |
Why?
|
| Coronary Artery Disease | 3 | 2022 | 6403 | 0.250 |
Why?
|
| Gagging | 1 | 2004 | 4 | 0.240 |
Why?
|
| Vasoconstriction | 1 | 2008 | 592 | 0.240 |
Why?
|
| Endoscopy | 9 | 2024 | 1851 | 0.240 |
Why?
|
| Apnea | 5 | 2016 | 195 | 0.240 |
Why?
|
| Body Mass Index | 21 | 2021 | 12953 | 0.240 |
Why?
|
| Phrenic Nerve | 4 | 2007 | 79 | 0.240 |
Why?
|
| Hypocapnia | 3 | 2017 | 38 | 0.240 |
Why?
|
| History of Medicine | 1 | 2005 | 42 | 0.240 |
Why?
|
| Aging | 6 | 2018 | 8710 | 0.240 |
Why?
|
| Reference Values | 9 | 2010 | 4920 | 0.240 |
Why?
|
| Disease Management | 2 | 2013 | 2508 | 0.240 |
Why?
|
| Feedback, Physiological | 1 | 2007 | 476 | 0.230 |
Why?
|
| Exhalation | 5 | 2018 | 181 | 0.230 |
Why?
|
| Acetazolamide | 3 | 2014 | 96 | 0.230 |
Why?
|
| Case-Control Studies | 19 | 2022 | 22176 | 0.230 |
Why?
|
| Aged | 49 | 2023 | 169310 | 0.220 |
Why?
|
| Tidal Volume | 8 | 2017 | 488 | 0.220 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 5 | 2016 | 1081 | 0.220 |
Why?
|
| Cardiovascular Diseases | 9 | 2023 | 15502 | 0.220 |
Why?
|
| Vascular Resistance | 1 | 2006 | 930 | 0.220 |
Why?
|
| Long-Term Potentiation | 4 | 2007 | 293 | 0.220 |
Why?
|
| Anesthesia, Local | 3 | 2000 | 277 | 0.210 |
Why?
|
| Sensitivity and Specificity | 11 | 2018 | 14665 | 0.210 |
Why?
|
| Atherosclerosis | 3 | 2023 | 3407 | 0.210 |
Why?
|
| Parasympatholytics | 2 | 2020 | 89 | 0.210 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2004 | 196 | 0.200 |
Why?
|
| Carbonic Anhydrase Inhibitors | 2 | 2013 | 91 | 0.200 |
Why?
|
| Hypertension | 4 | 2023 | 8540 | 0.200 |
Why?
|
| Electrooculography | 7 | 2018 | 113 | 0.190 |
Why?
|
| Tachycardia | 2 | 2014 | 600 | 0.190 |
Why?
|
| Laboratories | 1 | 2005 | 458 | 0.190 |
Why?
|
| Pulmonary Medicine | 1 | 2003 | 221 | 0.180 |
Why?
|
| Patient Readmission | 1 | 2015 | 3271 | 0.180 |
Why?
|
| Equipment and Supplies | 1 | 2003 | 273 | 0.180 |
Why?
|
| Cholinergic Agonists | 1 | 2000 | 75 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2013 | 3242 | 0.170 |
Why?
|
| Lung Compliance | 2 | 2018 | 200 | 0.170 |
Why?
|
| Shock | 1 | 2022 | 314 | 0.170 |
Why?
|
| Blood Circulation | 1 | 2020 | 248 | 0.170 |
Why?
|
| Snoring | 6 | 2024 | 209 | 0.170 |
Why?
|
| Cotinine | 1 | 2000 | 206 | 0.170 |
Why?
|
| Brain Waves | 2 | 2014 | 409 | 0.170 |
Why?
|
| Algorithms | 7 | 2021 | 14033 | 0.160 |
Why?
|
| Muscle, Smooth | 3 | 2014 | 926 | 0.160 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2016 | 1148 | 0.160 |
Why?
|
| Expiratory Reserve Volume | 2 | 2009 | 9 | 0.160 |
Why?
|
| Functional Residual Capacity | 4 | 2008 | 70 | 0.160 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2022 | 277 | 0.160 |
Why?
|
| Estradiol | 3 | 2016 | 1937 | 0.150 |
Why?
|
| Feedback | 4 | 2008 | 791 | 0.150 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2002 | 866 | 0.150 |
Why?
|
| Basal Metabolism | 2 | 2017 | 161 | 0.150 |
Why?
|
| Cheyne-Stokes Respiration | 2 | 2008 | 38 | 0.150 |
Why?
|
| Nicotinic Agonists | 1 | 2000 | 265 | 0.150 |
Why?
|
| Finite Element Analysis | 3 | 2005 | 438 | 0.150 |
Why?
|
| Adaptation, Physiological | 1 | 2004 | 1301 | 0.150 |
Why?
|
| Menopause | 3 | 2016 | 1646 | 0.140 |
Why?
|
| 4-Aminopyridine | 1 | 2017 | 80 | 0.140 |
Why?
|
| Lidocaine | 5 | 2014 | 538 | 0.140 |
Why?
|
| Nipecotic Acids | 1 | 2017 | 36 | 0.140 |
Why?
|
| Oxygen Consumption | 5 | 2017 | 1866 | 0.140 |
Why?
|
| Orthodontic Appliances | 1 | 2016 | 40 | 0.140 |
Why?
|
| Potassium Channel Blockers | 1 | 2017 | 161 | 0.140 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2001 | 376 | 0.140 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 1208 | 0.130 |
Why?
|
| Postmenopause | 2 | 2003 | 2513 | 0.130 |
Why?
|
| Treatment Outcome | 19 | 2022 | 64685 | 0.130 |
Why?
|
| Telemedicine | 1 | 2013 | 3052 | 0.130 |
Why?
|
| Propofol | 3 | 2015 | 603 | 0.130 |
Why?
|
| ROC Curve | 4 | 2018 | 3578 | 0.130 |
Why?
|
| Risk Assessment | 5 | 2023 | 23996 | 0.120 |
Why?
|
| Computers | 1 | 1998 | 593 | 0.120 |
Why?
|
| Respiration, Artificial | 3 | 2011 | 2630 | 0.120 |
Why?
|
| Nicotine | 1 | 2000 | 680 | 0.120 |
Why?
|
| Nocturnal Myoclonus Syndrome | 2 | 2006 | 51 | 0.120 |
Why?
|
| Young Adult | 21 | 2019 | 59260 | 0.120 |
Why?
|
| Oxyhemoglobins | 2 | 2006 | 211 | 0.120 |
Why?
|
| Analgesics, Opioid | 2 | 2016 | 3808 | 0.120 |
Why?
|
| Menstrual Cycle | 1 | 1998 | 539 | 0.120 |
Why?
|
| Masks | 2 | 2013 | 208 | 0.120 |
Why?
|
| Deep Sedation | 1 | 2015 | 118 | 0.120 |
Why?
|
| Oscillometry | 2 | 2014 | 150 | 0.110 |
Why?
|
| Sleep Deprivation | 3 | 2008 | 846 | 0.110 |
Why?
|
| Recruitment, Neurophysiological | 2 | 2010 | 33 | 0.110 |
Why?
|
| Hormones | 1 | 1998 | 869 | 0.110 |
Why?
|
| Phenotype | 7 | 2018 | 16592 | 0.110 |
Why?
|
| Monitoring, Physiologic | 4 | 2014 | 1779 | 0.110 |
Why?
|
| Neural Inhibition | 2 | 2010 | 590 | 0.110 |
Why?
|
| Receptors, Serotonin | 2 | 2004 | 208 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2019 | 2048 | 0.110 |
Why?
|
| Serotonin | 2 | 2004 | 1041 | 0.110 |
Why?
|
| Nose | 4 | 2000 | 521 | 0.100 |
Why?
|
| Linear Models | 5 | 2014 | 5872 | 0.100 |
Why?
|
| Trachea | 2 | 2012 | 1089 | 0.100 |
Why?
|
| Single-Blind Method | 5 | 2018 | 1574 | 0.100 |
Why?
|
| Supine Position | 4 | 2016 | 205 | 0.100 |
Why?
|
| Restless Legs Syndrome | 2 | 2005 | 233 | 0.100 |
Why?
|
| Double-Blind Method | 9 | 2020 | 12341 | 0.100 |
Why?
|
| Anesthetics, Local | 4 | 2014 | 997 | 0.100 |
Why?
|
| Markov Chains | 2 | 2013 | 966 | 0.100 |
Why?
|
| Airway Management | 1 | 2015 | 312 | 0.100 |
Why?
|
| Reticular Formation | 1 | 1991 | 59 | 0.100 |
Why?
|
| Helium | 2 | 2002 | 119 | 0.100 |
Why?
|
| Periodicity | 2 | 2003 | 348 | 0.100 |
Why?
|
| Time Factors | 16 | 2020 | 39969 | 0.100 |
Why?
|
| Prospective Studies | 14 | 2022 | 54423 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2006 | 6228 | 0.090 |
Why?
|
| Pulmonary Atelectasis | 1 | 2012 | 143 | 0.090 |
Why?
|
| Azabicyclo Compounds | 1 | 2011 | 68 | 0.090 |
Why?
|
| Action Potentials | 6 | 2011 | 1834 | 0.090 |
Why?
|
| Vagus Nerve | 2 | 2004 | 458 | 0.090 |
Why?
|
| Sleep Phase Chronotherapy | 1 | 2010 | 4 | 0.090 |
Why?
|
| Conscious Sedation | 1 | 2015 | 532 | 0.090 |
Why?
|
| Pulmonary Gas Exchange | 2 | 1990 | 379 | 0.090 |
Why?
|
| Kinesthesis | 1 | 2010 | 22 | 0.090 |
Why?
|
| Seizures | 2 | 2014 | 2957 | 0.090 |
Why?
|
| Cohort Studies | 11 | 2023 | 41495 | 0.090 |
Why?
|
| Work of Breathing | 1 | 1990 | 56 | 0.090 |
Why?
|
| Airway Remodeling | 1 | 2011 | 133 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2016 | 1468 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 235 | 0.090 |
Why?
|
| Peak Expiratory Flow Rate | 2 | 2018 | 144 | 0.090 |
Why?
|
| Reproducibility of Results | 8 | 2018 | 20100 | 0.090 |
Why?
|
| Perimenopause | 1 | 2011 | 142 | 0.090 |
Why?
|
| Police | 1 | 2011 | 157 | 0.080 |
Why?
|
| Sensory Thresholds | 1 | 2011 | 377 | 0.080 |
Why?
|
| Medicine | 1 | 1998 | 942 | 0.080 |
Why?
|
| Testosterone | 3 | 2001 | 2472 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 317 | 0.080 |
Why?
|
| Leptin | 2 | 2010 | 1597 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2017 | 1036 | 0.080 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2008 | 42 | 0.080 |
Why?
|
| Research Design | 1 | 2005 | 6180 | 0.080 |
Why?
|
| Plethysmography | 3 | 2014 | 175 | 0.080 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2013 | 1722 | 0.080 |
Why?
|
| Rats | 11 | 2009 | 23741 | 0.080 |
Why?
|
| Asthma | 3 | 1993 | 6234 | 0.080 |
Why?
|
| Vestibule, Labyrinth | 1 | 2010 | 234 | 0.080 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2010 | 170 | 0.080 |
Why?
|
| Risk Factors | 13 | 2020 | 74213 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 1230 | 0.070 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 5841 | 0.070 |
Why?
|
| Cost Savings | 1 | 2013 | 913 | 0.070 |
Why?
|
| Patient Selection | 2 | 2014 | 4244 | 0.070 |
Why?
|
| Neostigmine | 1 | 2007 | 68 | 0.070 |
Why?
|
| Acetylcholinesterase | 1 | 2007 | 156 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 10 | 2008 | 8181 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2006 | 2767 | 0.070 |
Why?
|
| Homocysteine | 1 | 2010 | 638 | 0.070 |
Why?
|
| Safety | 1 | 2011 | 1149 | 0.070 |
Why?
|
| Acclimatization | 1 | 1987 | 113 | 0.070 |
Why?
|
| Hydromorphone | 1 | 1987 | 70 | 0.070 |
Why?
|
| Physiology | 1 | 2007 | 111 | 0.070 |
Why?
|
| Prognosis | 3 | 2021 | 29629 | 0.070 |
Why?
|
| Autonomic Nervous System | 1 | 2011 | 703 | 0.070 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 1277 | 0.070 |
Why?
|
| Behavior Control | 1 | 2006 | 47 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2007 | 242 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 1625 | 0.060 |
Why?
|
| Equipment Failure | 1 | 2008 | 578 | 0.060 |
Why?
|
| Animals | 18 | 2013 | 168475 | 0.060 |
Why?
|
| Neurogenesis | 1 | 2011 | 863 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2010 | 1251 | 0.060 |
Why?
|
| Anthropometry | 3 | 2016 | 1349 | 0.060 |
Why?
|
| Nasal Obstruction | 1 | 2007 | 160 | 0.060 |
Why?
|
| Isoflurane | 1 | 2008 | 384 | 0.060 |
Why?
|
| Heart Failure | 3 | 2020 | 11671 | 0.060 |
Why?
|
| Video Recording | 1 | 2010 | 967 | 0.060 |
Why?
|
| Leuprolide | 2 | 2016 | 312 | 0.060 |
Why?
|
| Adolescent | 13 | 2016 | 88326 | 0.060 |
Why?
|
| Depression | 3 | 2016 | 8126 | 0.060 |
Why?
|
| Disulfiram | 1 | 2004 | 63 | 0.060 |
Why?
|
| Chronobiology Disorders | 1 | 2005 | 73 | 0.060 |
Why?
|
| Menstruation | 2 | 1983 | 307 | 0.060 |
Why?
|
| Israel | 1 | 2006 | 726 | 0.060 |
Why?
|
| Sex Factors | 7 | 2008 | 10554 | 0.060 |
Why?
|
| Metabolism | 1 | 1985 | 193 | 0.060 |
Why?
|
| Licensure | 1 | 2005 | 128 | 0.060 |
Why?
|
| Executive Function | 1 | 2012 | 1392 | 0.060 |
Why?
|
| Bradycardia | 2 | 2002 | 299 | 0.060 |
Why?
|
| Mouth | 2 | 2022 | 381 | 0.060 |
Why?
|
| Women's Health | 1 | 2013 | 2065 | 0.060 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2005 | 108 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 1987 | 367 | 0.060 |
Why?
|
| Oral Surgical Procedures | 1 | 2005 | 166 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2010 | 2244 | 0.050 |
Why?
|
| Encephalomyelitis, Equine | 1 | 1983 | 13 | 0.050 |
Why?
|
| Overweight | 1 | 2014 | 2417 | 0.050 |
Why?
|
| Affect | 1 | 2011 | 1486 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2006 | 992 | 0.050 |
Why?
|
| Neural Pathways | 2 | 2011 | 3060 | 0.050 |
Why?
|
| Elasticity | 1 | 2005 | 655 | 0.050 |
Why?
|
| Observer Variation | 2 | 2010 | 2606 | 0.050 |
Why?
|
| United States | 9 | 2020 | 72340 | 0.050 |
Why?
|
| Cats | 2 | 1996 | 975 | 0.050 |
Why?
|
| Hypogonadism | 2 | 1986 | 798 | 0.050 |
Why?
|
| Occlusal Splints | 1 | 2022 | 19 | 0.050 |
Why?
|
| Muscle Tonus | 2 | 2009 | 82 | 0.050 |
Why?
|
| Hyperoxia | 2 | 2014 | 258 | 0.050 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2006 | 324 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 1241 | 0.050 |
Why?
|
| Sound | 1 | 2024 | 257 | 0.050 |
Why?
|
| Education | 1 | 2005 | 537 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2010 | 5247 | 0.050 |
Why?
|
| Air | 1 | 2002 | 187 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2010 | 1213 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 17904 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2022 | 8633 | 0.040 |
Why?
|
| Body Constitution | 1 | 2001 | 273 | 0.040 |
Why?
|
| Piperazines | 1 | 2011 | 2523 | 0.040 |
Why?
|
| Breath Tests | 1 | 2002 | 299 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 3206 | 0.040 |
Why?
|
| Rotation | 1 | 2022 | 517 | 0.040 |
Why?
|
| Obesity, Abdominal | 1 | 2023 | 374 | 0.040 |
Why?
|
| Electrophysiology | 1 | 2003 | 1262 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2010 | 3208 | 0.040 |
Why?
|
| Leg | 1 | 2005 | 1088 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2001 | 241 | 0.040 |
Why?
|
| Metals | 1 | 2004 | 719 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2005 | 1674 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2005 | 895 | 0.040 |
Why?
|
| Bronchi | 1 | 2004 | 845 | 0.040 |
Why?
|
| Cardiac Output | 1 | 2002 | 831 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2022 | 326 | 0.040 |
Why?
|
| Computer Simulation | 3 | 2014 | 6241 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 15266 | 0.040 |
Why?
|
| Alpha Rhythm | 1 | 1999 | 111 | 0.040 |
Why?
|
| Insulin Resistance | 2 | 2010 | 3964 | 0.040 |
Why?
|
| Homeostasis | 1 | 2010 | 3323 | 0.040 |
Why?
|
| Forced Expiratory Volume | 3 | 1991 | 1814 | 0.040 |
Why?
|
| Electrodes, Implanted | 3 | 2010 | 840 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2005 | 1567 | 0.040 |
Why?
|
| Health Status | 1 | 2011 | 4077 | 0.040 |
Why?
|
| Motor Activity | 2 | 2008 | 2715 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 3826 | 0.040 |
Why?
|
| Anesthesia | 3 | 2017 | 1595 | 0.040 |
Why?
|
| Prolapse | 1 | 2018 | 63 | 0.040 |
Why?
|
| Movement | 1 | 2005 | 1478 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2358 | 0.040 |
Why?
|
| Circadian Rhythm | 2 | 2013 | 2576 | 0.040 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2011 | 726 | 0.040 |
Why?
|
| Progesterone | 2 | 1998 | 742 | 0.040 |
Why?
|
| Inspiratory Capacity | 1 | 2017 | 35 | 0.040 |
Why?
|
| Theta Rhythm | 1 | 1999 | 220 | 0.040 |
Why?
|
| Follicular Phase | 1 | 1998 | 143 | 0.040 |
Why?
|
| Luteal Phase | 1 | 1998 | 138 | 0.040 |
Why?
|
| Dopamine | 1 | 2005 | 1607 | 0.040 |
Why?
|
| Hospitalization | 2 | 2016 | 10721 | 0.040 |
Why?
|
| Eyelids | 1 | 1999 | 278 | 0.040 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 1 | 2016 | 34 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2022 | 12059 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2005 | 1819 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2000 | 439 | 0.030 |
Why?
|
| Decerebrate State | 1 | 1996 | 42 | 0.030 |
Why?
|
| Coronary Disease | 2 | 2003 | 5914 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2000 | 659 | 0.030 |
Why?
|
| Logistic Models | 3 | 2018 | 13255 | 0.030 |
Why?
|
| Antidepressive Agents | 2 | 2006 | 2897 | 0.030 |
Why?
|
| Respiratory Rate | 1 | 2017 | 176 | 0.030 |
Why?
|
| Fertility Agents, Female | 1 | 2016 | 101 | 0.030 |
Why?
|
| Research | 1 | 2005 | 1982 | 0.030 |
Why?
|
| Head | 1 | 2022 | 924 | 0.030 |
Why?
|
| Muscle Relaxation | 1 | 1996 | 138 | 0.030 |
Why?
|
| Weight Gain | 1 | 2006 | 2348 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2000 | 426 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2011 | 7968 | 0.030 |
Why?
|
| Morbidity | 1 | 2021 | 1752 | 0.030 |
Why?
|
| Nasopharynx | 1 | 1998 | 401 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2004 | 1436 | 0.030 |
Why?
|
| Microinjections | 1 | 1996 | 321 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8527 | 0.030 |
Why?
|
| Child | 5 | 2013 | 80158 | 0.030 |
Why?
|
| Vital Capacity | 3 | 1991 | 971 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 413 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2017 | 6345 | 0.030 |
Why?
|
| Cognition | 1 | 2012 | 6992 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2019 | 518 | 0.030 |
Why?
|
| Differential Threshold | 1 | 2014 | 80 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 10766 | 0.030 |
Why?
|
| Disease Progression | 3 | 2010 | 13510 | 0.030 |
Why?
|
| Benchmarking | 1 | 2021 | 1045 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2004 | 9319 | 0.030 |
Why?
|
| Ketanserin | 2 | 2004 | 24 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 58984 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2016 | 15633 | 0.030 |
Why?
|
| Military Personnel | 1 | 2003 | 1246 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2007 | 36426 | 0.030 |
Why?
|
| Hyperventilation | 1 | 2014 | 78 | 0.030 |
Why?
|
| Intercostal Muscles | 1 | 1993 | 26 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2007 | 4062 | 0.030 |
Why?
|
| Lung Diseases, Obstructive | 2 | 1987 | 308 | 0.030 |
Why?
|
| HIV-1 | 1 | 2010 | 6863 | 0.030 |
Why?
|
| Prevalence | 3 | 2006 | 15733 | 0.030 |
Why?
|
| Neck Muscles | 1 | 1993 | 100 | 0.030 |
Why?
|
| Forecasting | 2 | 2001 | 2928 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 2850 | 0.030 |
Why?
|
| Body Temperature | 2 | 2008 | 781 | 0.030 |
Why?
|
| Body Weight | 1 | 2003 | 4618 | 0.030 |
Why?
|
| Bethanechol Compounds | 1 | 1991 | 10 | 0.020 |
Why?
|
| Premenopause | 1 | 2016 | 1039 | 0.020 |
Why?
|
| Bethanechol | 1 | 1991 | 12 | 0.020 |
Why?
|
| Atmospheric Pressure | 1 | 1991 | 46 | 0.020 |
Why?
|
| Death, Sudden | 1 | 2013 | 301 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2013 | 358 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2017 | 909 | 0.020 |
Why?
|
| Carbachol | 1 | 1991 | 223 | 0.020 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 39106 | 0.020 |
Why?
|
| Methods | 1 | 1991 | 1067 | 0.020 |
Why?
|
| Age Factors | 4 | 2013 | 18399 | 0.020 |
Why?
|
| Estrogens | 1 | 1998 | 1522 | 0.020 |
Why?
|
| Aftercare | 1 | 2017 | 914 | 0.020 |
Why?
|
| Plethysmography, Whole Body | 1 | 1990 | 25 | 0.020 |
Why?
|
| Comorbidity | 3 | 2011 | 10508 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 7391 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 12973 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 140 | 0.020 |
Why?
|
| Pons | 1 | 1991 | 240 | 0.020 |
Why?
|
| Clozapine | 2 | 2004 | 504 | 0.020 |
Why?
|
| Mass Screening | 1 | 2006 | 5429 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 223 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 121 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2004 | 10212 | 0.020 |
Why?
|
| Recurrence | 1 | 2022 | 8466 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 325 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2015 | 9647 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 2 | 2012 | 2691 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6312 | 0.020 |
Why?
|
| Cephalometry | 1 | 1991 | 382 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 1474 | 0.020 |
Why?
|
| Ventilation-Perfusion Ratio | 2 | 1987 | 117 | 0.020 |
Why?
|
| Cross-Sectional Studies | 5 | 2011 | 26129 | 0.020 |
Why?
|
| Incidence | 3 | 2020 | 21355 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 962 | 0.020 |
Why?
|
| Health Planning Councils | 1 | 2008 | 11 | 0.020 |
Why?
|
| Professional Staff Committees | 1 | 2008 | 37 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 713 | 0.020 |
Why?
|
| Voluntary Health Agencies | 1 | 2008 | 38 | 0.020 |
Why?
|
| Electric Stimulation | 2 | 2004 | 1736 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2003 | 4485 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 5779 | 0.020 |
Why?
|
| North America | 1 | 2011 | 1276 | 0.020 |
Why?
|
| Vecuronium Bromide | 1 | 2007 | 33 | 0.020 |
Why?
|
| Glycopyrrolate | 1 | 2007 | 32 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 763 | 0.020 |
Why?
|
| Corticosterone | 1 | 2008 | 305 | 0.020 |
Why?
|
| Partial Pressure | 1 | 1987 | 245 | 0.020 |
Why?
|
| Actigraphy | 1 | 2011 | 520 | 0.020 |
Why?
|
| Atropine | 1 | 2007 | 244 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 1991 | 947 | 0.020 |
Why?
|
| Muscimol | 1 | 2006 | 70 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2008 | 322 | 0.020 |
Why?
|
| Reaction Time | 1 | 1993 | 2089 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2017 | 1906 | 0.020 |
Why?
|
| Muscarinic Antagonists | 1 | 2007 | 135 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 6374 | 0.020 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2007 | 143 | 0.020 |
Why?
|
| GABA Agonists | 1 | 2006 | 105 | 0.020 |
Why?
|
| Neurons | 1 | 2006 | 9463 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2016 | 1740 | 0.020 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2006 | 105 | 0.020 |
Why?
|
| Risk | 2 | 2011 | 9610 | 0.020 |
Why?
|
| Melanoma | 1 | 2004 | 5709 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2000 | 3980 | 0.020 |
Why?
|
| Habits | 1 | 2006 | 147 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2008 | 518 | 0.020 |
Why?
|
| Rabbits | 1 | 2012 | 4772 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2011 | 1047 | 0.020 |
Why?
|
| Occupational Health | 1 | 2011 | 806 | 0.020 |
Why?
|
| Dizocilpine Maleate | 1 | 2005 | 172 | 0.020 |
Why?
|
| Genital Diseases, Female | 1 | 2006 | 192 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 4021 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1987 | 667 | 0.010 |
Why?
|
| Cyclin A | 1 | 2004 | 60 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 12130 | 0.010 |
Why?
|
| Amino Acids | 1 | 2010 | 1718 | 0.010 |
Why?
|
| Haplotypes | 1 | 2010 | 2713 | 0.010 |
Why?
|
| Submarine Medicine | 1 | 2003 | 4 | 0.010 |
Why?
|
| Methysergide | 1 | 2003 | 28 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2004 | 293 | 0.010 |
Why?
|
| HIV Infections | 1 | 2010 | 17354 | 0.010 |
Why?
|
| American Heart Association | 1 | 2008 | 1039 | 0.010 |
Why?
|
| Residual Volume | 1 | 1983 | 41 | 0.010 |
Why?
|
| Quality Control | 1 | 2006 | 832 | 0.010 |
Why?
|
| Encephalitis Virus, Western Equine | 1 | 1983 | 7 | 0.010 |
Why?
|
| Serotonin Antagonists | 1 | 2003 | 145 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 1882 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2006 | 503 | 0.010 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2003 | 147 | 0.010 |
Why?
|
| Response Elements | 1 | 2004 | 309 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2008 | 851 | 0.010 |
Why?
|
| Memory | 1 | 2012 | 2193 | 0.010 |
Why?
|
| Neural Conduction | 1 | 2004 | 441 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2010 | 3968 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2014 | 3575 | 0.010 |
Why?
|
| Eye Neoplasms | 1 | 2004 | 307 | 0.010 |
Why?
|
| Placebos | 1 | 1987 | 1667 | 0.010 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2003 | 246 | 0.010 |
Why?
|
| Glutathione | 1 | 2004 | 583 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2004 | 502 | 0.010 |
Why?
|
| Copper | 1 | 2004 | 369 | 0.010 |
Why?
|
| Models, Animal | 1 | 2008 | 2112 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 13642 | 0.010 |
Why?
|
| Viral Load | 1 | 2010 | 3332 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1648 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 6019 | 0.010 |
Why?
|
| Canada | 1 | 2006 | 2122 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2010 | 5439 | 0.010 |
Why?
|
| Zinc | 1 | 2004 | 690 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2008 | 1555 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 2006 | 1132 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 1787 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 3415 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2003 | 1157 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 1271 | 0.010 |
Why?
|
| Dyspnea | 1 | 1987 | 1347 | 0.010 |
Why?
|
| Alleles | 1 | 2010 | 6864 | 0.010 |
Why?
|
| Ethanol | 1 | 1985 | 1324 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2004 | 2626 | 0.010 |
Why?
|
| Bronchitis | 1 | 1980 | 196 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 1229 | 0.010 |
Why?
|
| Pyridines | 1 | 2011 | 2875 | 0.010 |
Why?
|
| Epilepsy | 1 | 2014 | 3290 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 3066 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2011 | 3728 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 1173 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 3 | 1991 | 20568 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 2113 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2008 | 2118 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2008 | 1578 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 3113 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 2919 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2017 | 80647 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 4580 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 4431 | 0.010 |
Why?
|
| Air Pollution, Indoor | 1 | 2003 | 901 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 2472 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2010 | 2578 | 0.010 |
Why?
|
| Life Style | 1 | 2006 | 3917 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 2645 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 2155 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 5493 | 0.010 |
Why?
|
| Spirometry | 2 | 1987 | 929 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 7828 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 12463 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12690 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 2006 | 3222 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15936 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2008 | 5127 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2004 | 10451 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 4317 | 0.000 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 16990 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 18255 | 0.000 |
Why?
|
| Stroke | 1 | 2008 | 9758 | 0.000 |
Why?
|
| Colorado | 1 | 1984 | 165 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 21019 | 0.000 |
Why?
|
| Hyperbaric Oxygenation | 1 | 1982 | 165 | 0.000 |
Why?
|
| Pulmonary Alveoli | 1 | 1984 | 652 | 0.000 |
Why?
|
| China | 1 | 1984 | 2374 | 0.000 |
Why?
|
| Mice | 1 | 2004 | 81539 | 0.000 |
Why?
|